In vitro studies indicated that the antiangiogenic effect was due to the ability of bexarotene to inhibit endothelial cell growth and decrease tumour cell-mediated endothelial cell invasion through reduction of VEGF and EGF secretion from tumour cells. This evidence concerns the gene EGF and neoplasm.